Original Research
Published on 23 Dec 2022
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
in Multiple Sclerosis and Neuroimmunology
- 3,737 views
- 7 citations